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Abstract
A new VO2q complex with salicylic acid acetate (Aspirin) of formula C18H18Cl2O12V2 was synthesized and characterized. Its biological
effects upon cell proliferation, differentiation and promotion of tyrosine protein phosphorylation have been tested in two lines of osteoblast-
like cells in culture. q2000 Elsevier Science Inc. All rights reserved.
Keywords: VO2q/Aspirin complex; Aspirin; Bioactivity
Fig. 1. Salicylic acid acetate (Aspirin).
1. Introduction
Vanadium is a trace transition metal with relevant biolog-
ical properties [1]. For instance, it can pharmacologically
regulate the glucose level in the blood of diabetic animals
[2,3] and patients [4,5]. It can interact with different bio-
molecules in its anionic and cationic forms [6]. Although
the precise mechanisms of action are not completely known,
it has been suggested that vanadium inhibits protein tyrosine
phosphatases (PTPases) and thus regulates the level of pro-
tein tyrosine phosphorylation [7]. In this study we report the
synthesis and physicochemical characterization of a new
complex between VO2q cation and Aspirin (Fig. 1), a phar-
macological drug used worldwide. The bioactivity of the
VO2q/Aspirin complex has been tested on bone-related cells
in culture.
2. Results and discussion
2.1. Synthesis and physicochemical characterization of
VO2q/Aspirin complex
When a mixture of Aspirin and VOCl2 (50% aqueous
solution) in a molar ratio of 2/1 in 96% ethanol was stirred
* Corresponding author. Fax: q54-221-25-9485; e-mail: etcheverry@
nahuel.biol.unlp.edu.ar
under nitrogen atmosphere (pH 3.5, 0 8C), green oil was
formed. Successive washings with bidistilled water produced
a light green solid. It was filtered and immediately dried in a
vacuum line to avoid decomposition. Yield: 52%. Anal. Calc.
for C18H18Cl2O12V2 (599): C, 36.00; H, 3.00; V, 17.03; Cl,
11.85. Found: C, 36.26; H, 3.16; V, 16.95; Cl, 12.05%.
The electronic spectrum of the [VO(Aspirin)ClH2O]2
complex in a mixture of ethanol/water (1/1) under nitrogen
atmosphere shows two typical absorption bands [8] at 778
nm (´s36 My1 cmy1) and 608 nm (´s38 My1 cmy1).
IR (KBr disk spectrum): Aspirin: 1690 (vs) cmy1 (carbox-
ylic acid). VO2q/Aspirin complex: 1537 (s), 1403 (vs)
cmy1 (nas COOy and ns COOy, respectively) and 988 (s)
cmy1 (V_O stretching). The difference between the anti-
symmetric and symmetric stretching modes of the carboxy-
late group is indicative of the formation of a binuclear
complex with carboxylate bridges [9–11] (see Fig. 2). The
carbonyl (acetyl) stretching frequency (1754 cmy1)
remains unchanged upon coordination. The strong and broad
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Fig. 2. IR spectra of Aspirin (A) and VO2q/Aspirin complex (B). KBr
pellet technique.
Table 2
Effect of vanadyl (VO2q) and VO2q/Aspirin complex on MC3T3E1 cell
proliferation a





a MC3T3E1 osteoblast-like cells were grown in media alone or with the
addition of different concentrations of vanadium for 24 h. After this period,
cells were fixed and stained with crystal violet and the cell proliferation
evaluated by the absorbance at 540 nm. Results are expressed as
mean"SEM (ns9).
Table 1
Effect of vanadyl (VO2q) and VO2q/Aspirin complex on UMR106 cell
proliferation a





a UMR106 osteoblast-like cells were grown in media alone or with the
addition of different concentrations of vanadium for 24 h. After this period,
cells were fixed and stained with crystal violet and the cell proliferation
evaluated by the absorbance at 540 nm. Results are expressed as
mean"SEM (ns9).
band at about 3500 cmy1 (n OH) as well as the band at 1592
cmy1 (d OH2) indicate the presence of water in the coordi-
nation sphere of the vanadium centers [11].
2.2. Bioactivity of VO2q/Aspirin complex
In order to test the biological effects of vanadium com-
pounds, UMR106 and MC3T3E1 osteoblast-like cells were
cultured in DMEM without serum and with the addition of
different concentrations of VO2q cation or VO2q/Aspirin
complex (0, 10, 50, 100 mM) for 24 h at 37 8C. Then, the
cells were fixed and stained with crystal violet and the dye
extracted was quantitated at 540 nm [12]. As seen in Table
1, VO2q/Aspirin complex showed a biphasic effect upon
UMR106 cell proliferation: a stronger stimulatory effect of
VO2q/Aspirin complex than VO2q could be observed at low
concentrations (10 mM; *p-0.02), the complex being more
cytotoxic for these cells at higher doses (50–100 mM,
**p-0.001). These results suggest that the complex might
generate a stronger mitogenic signal than vanadyl at low
doses in these cells. However, at higher concentrations the
cytotoxic effect predominates, probably through the induc-
tion of reactive oxygen species [13]. On the other hand, both
vanadium(IV) compounds were inhibitory upon the prolif-
eration of MC3T3E1 cells in the whole range of tested con-
centrations (**p-0.002)(Table 2).
Osteoblast cell differentiation was evaluated using alkaline
phosphatase specific activity as a marker of mature osteo-
blastic phenotype [12]. VO2q/Aspirin complex and VO2q
both produced a similar inhibitory effect on UMR106 cell
differentiation up to 50 mM of vanadium compounds. At
higher doses there was a significant difference in the inhibi-
tory effect of the two vanadium derivatives, VO2q/Aspirin
being more potent than VO2q (75 mM, p-0.001; 100 mM,
p-0.01, ns9). Basal activity corresponded to 540"30
nmol/min/mg protein.
In addition, 10 mM VO2q/Aspirin complex induced evi-
dent morphological changes in MC3T3E1 cells similar to
those previously found for other vanadium compounds [14].
In general, after staining with Giemsa, the cultures displayed
cytoplasm condensation, loss of processes and the cells
became fusiform in shape.
To investigate the mechanism of action of vanadium com-
pounds, the tyrosine phosphorylation pattern induced by
vanadium derivatives was assessed by the Western blot
method (Fig. 3). MC3T3E1 cells were incubated overnight
with 50 mM of vanadium derivatives in serum-free medium.
As can be seen, VO2q and VO2q/Aspirin induced phospho-
rylation in tyrosine residues of several proteins, especially of
those of 26–45 kDa molecular weight, over the basal control
culture. Moreover, the complex showed a characteristic pat-
tern of four phosphorylated bands in the range of 36–45 kDa.
VO2q cation presented three bands in the 26–45 molecular
range but with a stronger intensity, while the basal culture
exhibited only two bands. Different vanadium compounds
induced tyrosine phosphorylation with different patterns, as
previously reported [14].
In conclusion, the present study has demonstrated that the
new VO2q/Aspirin complex produces biological effects on
osteoblast-like cells. This compound regulates cell prolifer-
ation and differentiation in a different way than VO2q. These
effects are partially associated with the ability of vanadium
derivatives to induce phosphorylation in tyrosine residues of
proteins by inhibition of PTPases. Like other vanadium deriv-
S.B. Etcheverry et al. / Journal of Inorganic Biochemistry 80 (2000) 169–171 171
Thursday May 25 10:57 AM StyleTag -- Journal: JIB (Journal of Inorganic Biochemistry) Article: 6369
Fig. 3. Western blot. Effect of vanadium(IV) compounds on the phospho-
tyrosin protein pattern of MC3T3E1 cells. Osteoblasts were incubated with
medium alone (lane 1) (control); vanadyl (lane 2); VO2q/Aspirin com-
plex (lane 3), at 50 mM for 24 h. After this time, proteins were separated
by electrophoresis and analyzed by the Western blot method using a
monoclonal anti-phosphotyrosine antibody. This figure is representative of
three independent experiments.
atives, VO2q/Aspirin induces morphological changes in
osteoblast-like cells.
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